

Supplementary Material Accompanying:

GraftIQ: A Hybrid Multi-Class Neural Network Integrating Clinical Insight for Multi-Outcome Prediction in Liver Transplant Recipients

Author list: Divya Sharma, PhD^{1,7*}, Neta Gotlieb, MD^{2*}, Daljeet Chahal, MD^{4*}, Sara Naimimohasses, PhD^{3,6}, Ankit Ray, BMSc³, Yoojin Han, BHSc³, Sara Gehlaut, BHSc³, Maryam Shojaee, MD³, Surabie Sivanendran, HBSc³, Maryam Naghibzadeh, MD³, Amirhossein Azhie, MD³, Sareh Keshavarzi, PhD², Kai Duan, MD⁵, Leslie Lilly, MD^{3,6}, Nazia Selzner, MD^{3,6}, Cynthia Tsien, MD^{3,6}, Elmar Jaeckel, MD^{3,6}, Wei Xu, PhD^{1**}, Mamatha Bhat, MD^{3,6**}

Affiliations:

1. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2. Department of Medicine, University of Ottawa, Ottawa, ON, Canada
3. Ajmera Transplant Program, University Health Network, Toronto, ON, Canada
4. Vancouver General Hospital, Division of Gastroenterology and Hepatology, and Liver Transplant Program of BC, University of British Columbia
5. Department of Pathology, University Health Network, Toronto, ON, Canada
6. Division of Gastroenterology & Hepatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
7. Department of Mathematics and Statistics, York University, Toronto, ON, Canada

*Co-First Authors, ** Co-Senior Authors

Table of Content	Page
Table of contents and List of Authors -----	1
Supplementary Table1 -----	2
Supplementary Table2 -----	4
Supplementary Table3 -----	4
Supplementary Table4 -----	5
Supplementary Table5 -----	5
Supplementary Table6 -----	6
Supplementary Table7 -----	7
Supplementary Figure 1 -----	8
Supplementary Figure 2 -----	9
Supplementary Figure 3 -----	10
Supplementary Figure 4 -----	11
Supplementary Figure 5 -----	12

Supplementary Table1: Primary Indication of Transplant in Subjects with at least one biopsy information

Covariate	N = 1791
Transplant Primary Indication	
Acute & Subacute Necrosis of Liver	1 (0)
Acute Fulminant Hepatic Failure – Viral – Other	1 (0)
Acute Intermittent Porphyrria	1 (0)
Acute on Chronic Liver Failure	1 (0)
Alagille’s Syndrome	3 (0)
Alcoholic Cirrhosis Of Liver	201 (11)
ALD Protocol / Alcoholic Cirrhosis Of Liver	10 (1)
Alpha I Anti-trypsin Deficiency	6 (0)
Alpha I Antitrypsin Deficiency	14 (1)
Amyloidosis	6 (0)
Autoimmune Active Hepatitis	46 (3)
Autoimmune Hepatitis	12 (1)
Biliary Atresia	2 (0)
Budd-Chiari Syndrome	9 (1)
Caroli’S Disease	2 (0)
Cirrhosis	1 (0)
Cirrhosis-Other	1 (0)
Cirrhosis, Unknown Etiology	44 (3)
Cryptogenic Cirrhosis	6 (0)
Cystic Fibrosis	4 (0)
Cystic Fibrosis-Cepacia Negative	3 (0)
Drug Induced Hepatitis	1 (0)
Epithelioid Hemangioendothelioma	1 (0)
Familial Cholestasis	1 (0)
Fulminant Hepatic Failure	44 (3)
Fulminant hepatic failure - acetaminophen	3 (0)
Fulminant hepatic failure - drug, other	1 (0)
Fulminant hepatitis B	1 (0)
Giant Cell Hepatitis	1 (0)
Glycogen Storage Disease	2 (0)
Haemochromatosis	4 (0)
Hemangioma, Any Site	1 (0)
Hepatitis - Unknown	3 (0)
Hepatitis B	134 (8)
Hepatitis C	601 (34)
Hepatitis C - Hepatitis C virus (HCV) RNA negative	53 (3)
Hepatitis C - Post Tx	1 (0)
Hepatitis C - RNA Pos	57 (3)
Hepatitis G	1 (0)

Hepatitis Non A/NonB	2 (0)
Hepatitis, Unspecified	1 (0)
Hepatopulmonary Syndrome	4 (0)
Hepatorenal syndrome	1 (0)
Idiopathic Fibrosing Alveolitis	1 (0)
Malignancy - cholangiocarcinoma	3 (0)
Malignancy - Fibrolamellar hepatoma	1 (0)
Malignancy - Hepatoma	15 (1)
Maple Syrup Urine Disease	1 (0)
Mesenteric Thrombosis	1 (0)
Metabolic Disorder – Hemochromatosis	4 (0)
Metabolic Disorder – Wilson’S Disease	1 (0)
Mitochondrial Disease	1 (0)
Nonalcoholic steatohepatitis (NASH)	121 (7)
Other Metabolics	3 (0)
Polycystic	1 (0)
Polycystic Liver Disease	4 (0)
Primary Biliary Cholangitis	90 (5)
Primary Sclerosing Cholangitis	141 (8)
Re-Tx: Chronic Biliary Obstruction	11 (1)
Re-Tx: Chronic Rejection	1 (0)
Re-Tx: Recurrent Disease	6 (0)
Re-Tx: Vessel Thrombosis	2 (0)
Recurrent Cholangitis	1 (0)
Retransplant	2 (0)
Retransplantation	31 (2)
Sarcoidosis	1 (0)
Sickle Cell Crisis	1 (0)
Sickle cell disease	2 (0)
Sub-Acute Fulminant	1 (0)
Subacute Fulminant Hepatic Failure – Viral – Other	1 (0)
Tylenol (acetaminophen) overdose	1 (0)
Wilson’S Disease	8 (0)
Missing	42

Supplementary Table 2: Tuning alpha and beta values to obtain the optimal alpha and beta values for bayesian fusion of clinical expertise and ML tool predictions.

alpha	beta	Overall AUC
0.1	0.9	0.887
0.2	0.8	0.902
0.3	0.7	0.897
0.4	0.6	0.866

Supplementary Table 3: Evaluation results using mean Area Under the Curve (AUC) metric and 95% Confidence Intervals (CI) on each diagnosis category in the external validation dataset using the proposed GraftIQ model

Categories	AUC [95% CI]
AIH	0.962 [0.949, 0.974]
BO	0.945 [0.933, 0.956]
Congestion	0.923 [0.909, 0.935]
HCV	0.922 [0.909, 0.933]
ACR	0.898 [0.886, 0.908]
MASH	0.951 [0.939, 0.964]

Supplementary Table 4: Hyperparameter optimization for multiclass Neural Network algorithm

Hyperparameter	Value	Search Range
Learning Rate	0.005	0.1, 0.01, 0.005, 0.001, 0.0005
Optimization solver	Adam	Stochastic Gradient Descent, Adam
Feature Scaling	Standard	Min-Max and Standard scaler
Number of Layers	3	1,3,5,7
Hidden units/ layer	24	12,24,48,96,192
Number of epochs	400	100-600
Dropout rate	0.5	0.3,0.4,0.5,0.6,0.7,0.8

Supplementary Table 5: Hyperparameter optimization for conventional Machine Learning Algorithms used for comparison to our proposed methodology.

Approaches	Parameter	Value	Search Range
Random Forest	No. of Trees	400	[10, 500]
	Mtry (No. of columns to randomly select at each level)	380	[50,400]
SVM Classifier	C	1	[0.1, 100]
	Kernel	sigmoid	'linear', 'poly', 'rbf', 'sigmoid'
Lasso Regression	alpha	0.005	[0.001, 0.1]
Ridge Regression	alpha	0.005	[0.001, 0.1]
Logistic Regression	C	0.001	[0.1,100]

Supplementary Table 6: Input variables and their missing rates

Variables	Definition of variables	Missing values (N=1791)	% Missing
Recipient gender	Sex (Recipient)	0	0
Recipient age	Age (Recipient)	0	0
WBC	White Blood cell (WBC)	73	3.8
platelets	Platelets	79	4.1
Creatinine	Serum Creatinine	75	3.9
INR	International normalized ratio	100	5.3
Albumin	Serum Albumin	407	21.5
Sodium	Serum Sodium (Na)	71	3.7
Tacrolimus serum level	Tacrolimus serum level	397	21
Cyclosporine serum level	Cyclosporine serum level	397	21
Hemoglobin	Hemoglobin	72	3.8
Bilirubin	Serum Total bilirubin	82	4.3
AST	Aspartate aminotransferase (AST)	72	3.8
ALT	Alanine aminotransferase (ALT)	60	3.1
ALP	Alkaline phosphatase (ALP)	67	3.5
MELD score	MELD score	0	0
Transplant primary indication	Primary indication for transplant	0	0
Donor Type (LDLT vs DDLT)	Living vs deceased donor	0	0
Weight	Weight (kg)	0	0
BMI	Body Mass Index (BMI)	0	0
Diabetes Mellitus	Diabetes Mellitus at transplant (Yes/ No)	0	0
Hypertension	Hypertension at transplant (Yes/No)	0	0
Dyslipidemia	Dyslipidemia at transplant (Yes/No)	0	0

Subgroup analysis based on primary indication for LT (HCV vs non-HCV):

In this study, we conducted a subgroup analysis based on the primary indication for liver transplantation (LT), specifically comparing patients transplanted for hepatitis C virus (HCV)-related liver disease to those with non-HCV etiologies. The purpose of this analysis was to assess the impact of the primary indication for transplant on the prediction of graft injury categories.


For the non-HCV cohort, we included 1,322 patients with acute cellular rejection (ACR), 102 with alloimmune hepatitis (AIH), 333 with biliary obstruction (BO), 112 with congestion, and 129 with metabolic associated steatohepatitis (MASH). As there was no HCV graft injury category for patients in the non-HCV primary transplant indication group, we retrained our model to test its performance on five graft injury categories (ACR, AIH, BO, congestion, and MASH) for this subgroup. In contrast, the HCV cohort comprised 566 patients with ACR, 82 with AIH, 147 with BO, 51 with congestion, 2,181 with recurrent HCV, and 119 with MASH. This stratification allowed us to compare the model's performance across different graft injury categories for both HCV and non-HCV patients, ensuring that our model remains robust and generalizable to modern transplant populations, where HCV is less prevalent.

Supplementary Table 7: Comparison of AUC values for the multiclass neural network (NN)-based machine learning (ML) model in predicting graft injury categories in HCV and non-HCV liver transplant recipients. The table shows the model's performance across six categories: Acute Cellular Rejection (ACR), Alloimmune Hepatitis (AIH), Biliary Obstruction (BO), Congestion, HCV recurrence, and Metabolic Associated Steatohepatitis (MASH). AUC values demonstrate consistent model performance across both HCV and non-HCV cohorts, indicating the model's robustness.

Category	AUC multiclass NN based ML model	AUC multiclass NN based ML model
	Primary indication of transplant HCV	Primary indication of transplant Non-HCV
ACR	0.781	0.769
AIH	0.919	0.907
BO	0.908	0.896
Congestion	0.915	0.903
HCV	0.864	-
MASH	0.910	0.902


Supplementary Figure 1: Important variables for predicting diagnosis in AIH category

AIH



Supplementary Figure 2: Important variables for predicting diagnosis in congestion category


Congestion



Gradient obtained using Neural Network


Supplementary Figure 3: Important variables for predicting diagnosis in BO category

Biliary obstruction (BO)



Supplementary Figure 4: Important variables for predicting diagnosis in HCV category


HCV



Gradient obtained using Neural Network

Supplementary Figure 5: Important variables for predicting diagnosis in MASH category

MASH



Gradient obtained using Neural Network